Overlapping molecular pathways between cannabinoid receptors type 1 and 2 and estrogens/androgens on the periphery and their involvement in the pathogenesis of common diseases (Review)

Dobovišek,Luka; Hojnik,Marko; Ferk,Polonca

doi:10.3892/ijmm.2016.2779

Overlapping molecular pathways between cannabinoid receptors type 1 and 2 and estrogens/androgens on the periphery and their involvement in the pathogenesis of common diseases (Review)

Authors:
- Luka Dobovišek
- Marko Hojnik
- Polonca Ferk
View Affiliations

Affiliations: Department of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Maribor, SI-2000 Maribor, Slovenia
Published online on: October 17, 2016 https://doi.org/10.3892/ijmm.2016.2779
Pages: 1642-1651

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The physiological and pathophysiological roles of sex hormones have been well documented and the modulation of their effects is applicable in many current treatments. On the other hand, the physiological role of endocannabinoids is not yet clearly understood and the endocannabinoid system is considered a relatively new therapeutic target. The physiological association between sex hormones and cannabinoids has been investigated in several studies; however, its involvement in the pathophysiology of common human diseases has been studied separately. Herein, we present the first systematic review of molecular pathways that are influenced by both the cannabinoids and sex hormones, including adenylate cyclase and protein kinase A, epidermal growth factor receptor, cyclic adenosine monophosphate response element-binding protein, vascular endothelial growth factor, proto-oncogene serine/threonine-protein kinase, mitogen-activated protein kinase, phosphatidylinositol-4,5-bisphosphate 3-kinase, C-Jun N-terminal kinase and extracellular-signal-regulated kinases 1/2. Most of these influence cell proliferative activity. Better insight into this association may prove to be beneficial for the development of novel pharmacological treatment strategies for many common diseases, including breast cancer, endometrial cancer, prostate cancer, osteoporosis and atherosclerosis. The associations between cannabinoids, estrogens and androgens under these conditions are also presented and the molecular interactions are highlighted.

View Figures

View References

1	Han S, Thatte J, Buzard DJ and Jones RM: Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. J Med Chem. 56:8224–8256. 2013. View Article : Google Scholar : PubMed/NCBI
2	Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T and Greasley PJ: The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 152:1092–1101. 2007. View Article : Google Scholar : PubMed/NCBI
3	McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM and Bradshaw HB: N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 11:442010. View Article : Google Scholar : PubMed/NCBI
4	Brown AJ: Novel cannabinoid receptors. Br J Pharmacol. 152:567–575. 2007. View Article : Google Scholar : PubMed/NCBI
5	Starowicz K, Nigam S and Di Marzo V: Biochemistry and pharmacology of endovanilloids. Pharmacol Ther. 114:13–33. 2007. View Article : Google Scholar : PubMed/NCBI
6	Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM and Webb P: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 74:311–317. 2000. View Article : Google Scholar
7	Hammes SR and Levin ER: Minireview: Recent advances in extranuclear steroid receptor actions. Endocrinology. 152:4489–4495. 2011. View Article : Google Scholar : PubMed/NCBI
8	Coleman KM and Smith CL: Intracellular signaling pathways: Nongenomic actions of estrogens and ligand-independent activation of estrogen receptors. Front Biosci. 6:D1379–D1391. 2001. View Article : Google Scholar : PubMed/NCBI
9	Prossnitz ER, Arterburn JB and Sklar LA: GPR30: A G protein-coupled receptor for estrogen. Mol Cell Endocrinol. 265–266:138–142. 2007. View Article : Google Scholar
10	Paterni I, Granchi C, Katzenellenbogen JA and Minutolo F: Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential. Steroids. 90:13–29. 2014. View Article : Google Scholar : PubMed/NCBI
11	John E: Hall: Guyton and Hall Textbook of Medical Physiology. 12th edition. Saunders; pp. 991–992. 2010
12	Tyrey L: delta-9-Tetrahydrocannabinol suppression of episodic luteinizing hormone secretion in the ovariectomized rat. Endocrinology. 102:1808–1814. 1978. View Article : Google Scholar : PubMed/NCBI
13	Tyrey L: delta 9-Tetrahydrocannabinol: A potent inhibitor of episodic luteinizing hormone secretion. J Pharmacol Exp Ther. 213:306–308. 1980.PubMed/NCBI
14	Kumar MS and Chen CL: Effect of an acute dose of delta 9-THC on hypothalamic luteinizing hormone releasing hormone and met-enkephalin content and serum levels of testosterone and corticosterone in rats. Subst Alcohol Actions Misuse. 4:37–43. 1983.PubMed/NCBI
15	Scorticati C, Fernández-Solari J, De Laurentiis A, Mohn C, Prestifilippo JP, Lasaga M, Seilicovich A, Billi S, Franchi A, McCann SM, et al: The inhibitory effect of anandamide on luteinizing hormone-releasing hormone secretion is reversed by estrogen. Proc Natl Acad Sci USA. 101:11891–11896. 2004. View Article : Google Scholar : PubMed/NCBI
16	Gammon CM, Freeman GM Jr, Xie W, Petersen SL and Wetsel WC: Regulation of gonadotropin-releasing hormone secretion by cannabinoids. Endocrinology. 146:4491–4499. 2005. View Article : Google Scholar : PubMed/NCBI
17	Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA and Gilula NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:83–87. 1996. View Article : Google Scholar : PubMed/NCBI
18	MacCarrone M, De Felici M, Bari M, Klinger F, Siracusa G and Finazzi-Agrò A: Downregulation of anandamide hydrolase in mouse uterus by sex hormones. Eur J Biochem. 267:2991–2997. 2000. View Article : Google Scholar : PubMed/NCBI
19	El-Talatini MR, Taylor AH and Konje JC: The relationship between plasma levels of the endocannabinoid, anandamide, sex steroids, and gonadotrophins during the menstrual cycle. Fertil Steril. 93:1989–1996. 2010. View Article : Google Scholar
20	Gorzalka BB and Dang SS: Minireview: Endocannabinoids and gonadal hormones: bidirectional interactions in physiology and behavior. Endocrinology. 153:1016–1024. 2012. View Article : Google Scholar : PubMed/NCBI
21	Rossi F, Bellini G, Luongo L, Mancusi S, Torella M, Tortora C, Manzo I, Guida F, Nobili B, de Novellis V and Maione S: The 17-β-oestradiol inhibits osteoclast activity by increasing the cannabinoid CB2 receptor expression. Pharmacol Res. 68:7–15. 2013. View Article : Google Scholar
22	Notarnicola M, Messa C, Orlando A, Bifulco M, Laezza C, Gazzerro P and Caruso MG: Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. Scand J Gastroenterol. 43:66–72. 2008. View Article : Google Scholar : PubMed/NCBI
23	Riebe CJ, Hill MN, Lee TT, Hillard CJ and Gorzalka BB: Estrogenic regulation of limbic cannabinoid receptor binding. Psychoneuroendocrinology. 35:1265–1269. 2010. View Article : Google Scholar : PubMed/NCBI
24	Kumar P and Song ZH: CB2 cannabinoid receptor is a novel target for third-generation selective estrogen receptor modulators bazedoxifene and lasofoxifene. Biochem Biophys Res Commun. 443:144–149. 2014. View Article : Google Scholar
25	Prather PL, FrancisDevaraj F, Dates CR, Greer AK, Bratton SM, Ford BM, Franks LN and Radominska-Pandya A: CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen. Biochem Biophys Res Commun. 441:339–343. 2013. View Article : Google Scholar : PubMed/NCBI
26	Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzmán M and Di Marzo V: Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett. 463:235–240. 1999. View Article : Google Scholar : PubMed/NCBI
27	Gu Q and Moss RL: 17 beta-Estradiol potentiates kainate-induced currents via activation of the cAMP cascade. J Neurosci. 16:3620–3629. 1996.PubMed/NCBI
28	Picotto G, Massheimer V and Boland R: Acute stimulation of intestinal cell calcium influx induced by 17 beta-estradiol via the cAMP messenger system. Mol Cell Endocrinol. 119:129–134. 1996. View Article : Google Scholar : PubMed/NCBI
29	Watters JJ and Dorsa DM: Transcriptional effects of estrogen on neuronal neurotensin gene expression involve cAMP/protein kinase A-dependent signaling mechanisms. J Neurosci. 18:6672–6680. 1998.PubMed/NCBI
30	Szego CM and Davis JS: Adenosine 3′,5′-monophosphate in rat uterus: Acute elevation by estrogen. Proc Natl Acad Sci USA. 58:1711–1718. 1967. View Article : Google Scholar
31	Mimeault M, Pommery N, Wattez N, Bailly C and Hénichart JP: Anti-fn of epidermal growth factor receptor downregulation and ceramide production. Prostate. 56:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
32	Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou X, Groopman JE and Ganju RK: Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila). 4:65–75. 2011. View Article : Google Scholar
33	Driggers PH and Segars JH: Estrogen action and cytoplasmic signaling pathways. Part II: The role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab. 13:422–427. 2002. View Article : Google Scholar : PubMed/NCBI
34	O'Lone R, Frith MC, Karlsson EK and Hansen U: Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 18:1859–1875. 2004. View Article : Google Scholar : PubMed/NCBI
35	Marino M, Galluzzo P and Ascenzi P: Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics. 7:497–508. 2006. View Article : Google Scholar
36	Bosier B, Hermans E and Lambert D: Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor. Br J Pharmacol. 155:24–33. 2008. View Article : Google Scholar : PubMed/NCBI
37	Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M and Di Marzo V: Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. 141:118–126. 2000.
38	Watters JJ, Chun TY, Kim YN, Bertics PJ and Gorski J: Estrogen modulation of prolactin gene expression requires an intact mitogen-activated protein kinase signal transduction pathway in cultured rat pituitary cells. Mol Endocrinol. 14:1872–1881. 2000. View Article : Google Scholar : PubMed/NCBI
39	Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V and Bifulco M: Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: Actions on signals involved in angiogenesis and metastasis. FASEB J. 17:1771–1773. 2003.PubMed/NCBI
40	Blázquez C, González-Feria L, Alvarez L, Haro A, Casanova ML and Guzmán M: Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 64:5617–5623. 2004. View Article : Google Scholar : PubMed/NCBI
41	Mueller MD, Vigne JL, Minchenko A, Lebovic DI, Leitman DC and Taylor RN: Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc Natl Acad Sci USA. 97:10972–10977. 2000. View Article : Google Scholar : PubMed/NCBI
42	Stoner M, Wang F, Wormke M, Nguyen T, Samudio I, Vyhlidal C, Marme D, Finkenzeller G and Safe S: Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins. J Biol Chem. 275:22769–22779. 2000. View Article : Google Scholar : PubMed/NCBI
43	Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M and Guzmán M: Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 6:313–319. 2000. View Article : Google Scholar : PubMed/NCBI
44	Klinge CM, Blankenship KA, Risinger KE, Bhatnagar S, Noisin EL, Sumanasekera WK, Zhao L, Brey DM and Keynton RS: Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J Biol Chem. 280:7460–7468. 2005. View Article : Google Scholar
45	Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K and Cobb MH: Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr Rev. 22:153–183. 2001.PubMed/NCBI
46	Acconcia F, Totta P, Ogawa S, Cardillo I, Inoue S, Leone S, Trentalance A, Muramatsu M and Marino M: Survival versus apoptotic 17beta-estradiol effect: Role of ER alpha and ER beta activated non-genomic signaling. J Cell Physiol. 203:193–201. 2005. View Article : Google Scholar
47	Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R and Grohe C: Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem. 275:18447–18453. 2000. View Article : Google Scholar : PubMed/NCBI
48	Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, et al: International Union of Basic and Clinical Pharmacology. LXXIX Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacol Rev. 62:588–631. 2010. View Article : Google Scholar : PubMed/NCBI
49	Ramer R, Weinzierl U, Schwind B, Brune K and Hinz B: Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. Mol Pharmacol. 64:1189–1198. 2003. View Article : Google Scholar : PubMed/NCBI
50	Pisanti S, Picardi P, D'Alessandro A, Laezza C and Bifulco M: The endocannabinoid signaling system in cancer. Trends Pharmacol Sci. 34:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
51	Ellert-Miklaszewska A, Kaminska B and Konarska L: Cannabinoids downregulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal. 17:25–37. 2005. View Article : Google Scholar
52	Haynes MP, Li L, Sinha D, Russell KS, Hisamoto K, Baron R, Collinge M, Sessa WC and Bender JR: Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem. 278:2118–2123. 2003. View Article : Google Scholar
53	Marino M, Acconcia F and Trentalance A: Biphasic estradiol-induced AKT phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol Biol Cell. 14:2583–2591. 2003. View Article : Google Scholar : PubMed/NCBI
54	Gaub MP, Bellard M, Scheuer I, Chambon P and Sassone-Corsi P: Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell. 63:1267–1276. 1990. View Article : Google Scholar : PubMed/NCBI
55	Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ and Scanlan TS: Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science. 277:1508–1510. 1997. View Article : Google Scholar : PubMed/NCBI
56	Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T and Manolagas SC: Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest. 111:1651–1664. 2003. View Article : Google Scholar : PubMed/NCBI
57	Sarfaraz S, Afaq F, Adhami VM, Malik A and Mukhtar H: Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem. 281:39480–39491. 2006. View Article : Google Scholar : PubMed/NCBI
58	Cianchi F, Papucci L, Schiavone N, Lulli M, Magnelli L, Vinci MC, Messerini L, Manera C, Ronconi E, Romagnani P, et al: Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells. Clin Cancer Res. 14:7691–7700. 2008. View Article : Google Scholar : PubMed/NCBI
59	Guo Y, Wang H, Okamoto Y, Ueda N, Kingsley PJ, Marnett LJ, Schmid HH, Das SK and Dey SK: N-acylphosphatidylethanolamine-hydrolyzing phospholipase D is an important determinant of uterine anandamide levels during implantation. J Biol Chem. 280:23429–23432. 2005. View Article : Google Scholar : PubMed/NCBI
60	Tsuboi K, Okamoto Y, Ikematsu N, Inoue M, Shimizu Y, Uyama T, Wang J, Deutsch DG, Burns MP, Ulloa NM, et al: Enzymatic formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -independent pathways. Biochim Biophys Acta. 1811:565–577. 2011. View Article : Google Scholar : PubMed/NCBI
61	Urquhart P, Nicolaou A and Woodward DF: Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases. Biochim Biophys Acta. 1851:366–376. 2015. View Article : Google Scholar
62	Tamura M, Deb S, Sebastian S, Okamura K and Bulun SE: Estrogen up-regulates cyclooxygenase-2 via estrogen receptor in human uterine microvascular endothelial cells. Fertil Steril. 81:1351–1356. 2004. View Article : Google Scholar : PubMed/NCBI
63	Higa GM and Fell RG: Sex hormone receptor repertoire in breast cancer. Int J Breast Cancer. 2013:2840362013. View Article : Google Scholar : PubMed/NCBI
64	Caffarel MM, Sarrió D, Palacios J, Guzmán M and Sánchez C: Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 66:6615–6621. 2006. View Article : Google Scholar : PubMed/NCBI
65	Shrivastava A, Kuzontkoski PM, Groopman JE and Prasad A: Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther. 10:1161–1172. 2011. View Article : Google Scholar : PubMed/NCBI
66	Murase R, Kawamura R, Singer E, Pakdel A, Sarma P, Judkins J, Elwakeel E, Dayal S, Martinez-Martinez E, Amere M, et al: Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. Br J Pharmacol. 171:4464–4477. 2014. View Article : Google Scholar : PubMed/NCBI
67	Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH and Ganju RK: Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther. 8:3117–3129. 2009. View Article : Google Scholar : PubMed/NCBI
68	McKallip RJ, Nagarkatti M and Nagarkatti PS: Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol. 174:3281–3289. 2005. View Article : Google Scholar : PubMed/NCBI
69	SGO Clinical Practice Endometrial Cancer Working Group; Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Villella J, Herzog T and Abu Shahin F; Society of Gynecologic Oncology Clinical Practice Committee: Endometrial cancer: A review and current management strategies: part I. Gynecol Oncol. 134:385–392. 2014. View Article : Google Scholar : PubMed/NCBI
70	Tangen IL, Werner HM, Berg A, Halle MK, Kusonmano K, Trovik J, Hoivik EA, Mills GB, Krakstad C and Salvesen HB: Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. Eur J Cancer. 50:3003–3010. 2014. View Article : Google Scholar : PubMed/NCBI
71	Ayakannu A, Taylor AH, Marczylo TH, Willets JM, Brown L, Davies Q, Moss E and Konje JC: Association of cannabinoid receptor expression with anandamide concentrations in endometrial cancer. Lancet Volume. 383:S232014. View Article : Google Scholar
72	Guida M, Ligresti A, De Filippis D, D'Amico A, Petrosino S, Cipriano M, Bifulco G, Simonetti S, Orlando P, Insabato L, et al: The levels of the endocannabinoid receptor CB2 and its ligand 2-arachidonoylglycerol are elevated in endometrial carcinoma. Endocrinology. 151:921–928. 2010. View Article : Google Scholar : PubMed/NCBI
73	Raisz LG: Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest. 115:3318–3325. 2005. View Article : Google Scholar : PubMed/NCBI
74	Centrella M and McCarthy TL: Estrogen receptor dependent gene expression by osteoblasts - direct, indirect, circumspect, and speculative effects. Steroids. 77:174–184. 2012. View Article : Google Scholar
75	Bilezikian JP, Raisz LG and Martin TJ: Principles of Bone Biology. 3rd edition. Elsevier; Amsterdam: pp. 855–885. 2008
76	Bradford PG, Gerace KV, Roland RL and Chrzan BG: Estrogen regulation of apoptosis in osteoblasts. Physiol Behav. 99:181–185. 2010. View Article : Google Scholar :
77	Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, et al: Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA. 103:696–701. 2006. View Article : Google Scholar : PubMed/NCBI
78	Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R and Fride E: HU-308: A specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA. 96:14228–14233. 1999. View Article : Google Scholar : PubMed/NCBI
79	Hojnik M, Dobovišek L, Knez Ž and Ferk P: A synergistic interaction of 17-β-estradiol with specific cannabinoid receptor type 2 antagonist/inverse agonist on proliferation activity in primary human osteoblasts. Biomed Rep. 3:554–558. 2015.PubMed/NCBI
80	Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL and Mach F: Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 434:782–786. 2005. View Article : Google Scholar : PubMed/NCBI
81	Paganini-Hill A, Dworsky R and Krauss RM: Hormone replacement therapy, hormone levels, and lipoprotein cholesterol concentrations in elderly women. Am J Obstet Gynecol. 174:897–902. 1996. View Article : Google Scholar : PubMed/NCBI
82	Boosani CS and Sudhakar YA: Proteolytically derived endogenous angioinhibitors originating from the extracellular matrix. Pharmaceuticals (Basel). 4:1551–1577. 2011. View Article : Google Scholar
83	Deroo BJ and Korach KS: Estrogen receptors and human disease. J Clin Invest. 116:561–570. 2006. View Article : Google Scholar : PubMed/NCBI
84	Murphy E: Estrogen signaling and cardiovascular disease. Circ Res. 109:687–696. 2011. View Article : Google Scholar : PubMed/NCBI
85	Dol-Gleizes F, Paumelle R, Visentin V, Marés AM, Desitter P, Hennuyer N, Gilde A, Staels B, Schaeffer P and Bono F: Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 29:12–18. 2009. View Article : Google Scholar
86	Pacher P: Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: New hopes, old concerns? Arterioscler Thromb Vasc Biol. 29:7–9. 2009. View Article : Google Scholar :
87	Mach F, Montecucco F and Steffens S: Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol. 153:290–298. 2008. View Article : Google Scholar
88	Chiurchiù V, Lanuti M, Catanzaro G, Fezza F, Rapino C and Maccarrone M: Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. Atherosclerosis. 233:55–63. 2014. View Article : Google Scholar : PubMed/NCBI
89	Collot-Teixeira S, Martin J, McDermott-Roe C, Poston R and McGregor JL: CD36 and macrophages in atherosclerosis. Cardiovasc Res. 75:468–477. 2007. View Article : Google Scholar : PubMed/NCBI
90	Heinlein CA and Chang C: The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol. 16:2181–2187. 2002. View Article : Google Scholar : PubMed/NCBI
91	Michels G and Hoppe UC: Rapid actions of androgens. Front Neuroendocrinol. 29:182–198. 2008. View Article : Google Scholar
92	Cohen S: The 94-day cannabis study. Ann NY Acad Sci. 282:211–220. 1976. View Article : Google Scholar : PubMed/NCBI
93	Block RI, Farinpour R and Schlechte JA: Effects of chronic marijuana use on testosterone, luteinizing hormone, follicle stimulating hormone, prolactin and cortisol in men and women. Drug Alcohol Depend. 28:121–128. 1991. View Article : Google Scholar : PubMed/NCBI
94	Dalterio S, Bartke A and Burstein S: Cannabinoids inhibit testosterone secretion by mouse testes in vitro. Science. 196:1472–1473. 1977. View Article : Google Scholar : PubMed/NCBI
95	Dixit VP, Sharma VN and Lohiya NK: The effect of chronically administered cannabis extract on the testicular function of mice. Eur J Pharmacol. 26:111–114. 1974. View Article : Google Scholar : PubMed/NCBI
96	Ghosh SP, Chatterjee TK and Ghosh JJ: Antiandrogenic effect of delta-9-tetrahydrocannabinol in adult castrated rats. J Reprod Fertil. 62:513–517. 1981. View Article : Google Scholar : PubMed/NCBI
97	Dixit VP, Gupta CL and Agrawal M: Testicular degeneration and necrosis induced by chronic administration of cannabis extract in dogs. Endokrinologie. 69:299–305. 1977.PubMed/NCBI
98	Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C and Auricchio F: Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J. 19:5406–5417. 2000. View Article : Google Scholar : PubMed/NCBI
99	Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA and Marcelli M: Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 64:7156–7168. 2004. View Article : Google Scholar : PubMed/NCBI
100	Li J and Al-Azzawi F: Mechanism of androgen receptor action. Maturitas. 63:142–148. 2009. View Article : Google Scholar : PubMed/NCBI
101	Taichman RS, Loberg RD, Mehra R and Pienta KJ: The evolving biology and treatment of prostate cancer. J Clin Invest. 117:2351–2361. 2007. View Article : Google Scholar : PubMed/NCBI
102	Bonaccorsi L, Nosi D, Quercioli F, Formigli L, Zecchi S, Maggi M, Forti G and Baldi E: Prostate cancer: A model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model. Steroids. 73:1030–1037. 2008. View Article : Google Scholar : PubMed/NCBI
103	Bonaccorsi L, Nosi D, Muratori M, Formigli L, Forti G and Baldi E: Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. J Mol Endocrinol. 38:51–66. 2007. View Article : Google Scholar : PubMed/NCBI
104	Purohit V, Ahluwahlia BS and Vigersky RA: Marihuana inhibits dihydrotestosterone binding to the androgen receptor. Endocrinology. 107:848–850. 1980. View Article : Google Scholar : PubMed/NCBI
105	Grech A, Breck J and Heidelbaugh J: Adverse effects of testosterone replacement therapy: An update on the evidence and controversy. Ther Adv Drug Saf. 5:190–200. 2014. View Article : Google Scholar : PubMed/NCBI
106	Ahmed A, Ali S and Sarkar FH: Advances in androgen receptor targeted therapy for prostate cancer. J Cell Physiol. 229:271–276. 2014. View Article : Google Scholar
107	Morales P, Vara D, Goméz-Cañas M, Zúñiga MC, Olea-Azar C, Goya P, Fernández-Ruiz J, Díaz-Laviada I and Jagerovic N: Synthetic cannabinoid quinones: Preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity. Eur J Med Chem. 70:111–119. 2013. View Article : Google Scholar : PubMed/NCBI
108	De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P and Di Marzo V: Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: Pro-apoptotic effects and underlying mechanisms. Br J Pharmacol. 168:79–102. 2013. View Article : Google Scholar :